The Bill & Melinda Gates Foundation today announced that Trevor Mundel, who currently heads the giant development team pharmaceutical Novartis International AG, will take over as president of its global health program on 1 December. Mundell, a scientist and physician pharmaceutical, replace Tachi Yamada, who retired as chairman of the program in June.
The program, which draws from $ 36.3 billion endowment of the Gates Foundation, fundraising, development and implementation of projects to fight against diseases such as HIV / AIDS, malaria, malnutrition, polio and tuberculosis in poor countries. To date, the program has granted $ 14.7 billion in grants, including funds in efforts to understand the disease kwashiorkor malnutrition and develop potential treatments against HIV.
Several pharmaceutical companies, including Alkermes Inc., Parke-Davis, Pfizer and Novartis, Mundel brought to shake their research and development programs and streamline the translation process from basic research on new drugs. Mundell is a big proponent of the "modeling and simulation" according to a 09 article in the Bio-IT World, using complex mathematical models to optimize and accelerate all biochemical medicines mechanisms for decision making and profits.
The appointment of Mundel probably reflects the will of the Gates Foundation to apply this approach to their health plans and drug development, said Denise DeMan-Williams, founder and CEO of the biotech Bench International recruitment firm (who recruited Mundel Novartis for work). "Trevor is someone who is probably several years ahead of his time," she said. "I think he will do flawlessly."
0 Komentar